PathogenDx Receives Federal Grant From the NIH As Part of the RADx Program - PathogenDx Receives Federal Grant From the NIH As Part of the RADx Program - POCTRN

In response to the COVID-19 pandemic, the Rapid Acceleration of Diagnostics (RADxsm) initiative was formed to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19.

Learn More >>

Agrégateur de contenus

angle-left PathogenDx Receives Federal Grant From the NIH As Part of the RADx Program

Rapid Scaling Up of Covid-19 Diagnostic Testing in the United States — The NIH RADx Initiative

The capital will be used to scale up testing capacity of PathogenDx's Microarray Assay for COVID-19 testing nationally


SCOTTSDALE, Ariz., July 28, 2020 /PRNewswire/ -- PathogenDx, Inc., an Arizona based technology company which has developed an ultra-accurate DNA-based customized pathogen testing platform for the food, agricultural and health sectors, announced today that the company has been awarded a federal grant from the National Institutes of Health (NIH) under their Rapid Acceleration of Diagnostic (RADx) program. The resources will be used to increase the testing capacity of PathogenDx's DetectX-Rv Microarray Assay for COVID-19 testing to a national level.

Read the full release here >